schizophrenia

pivot change turnaround direction walk away
Biotech

Boehringer cuts ties to Nxera's phase 2-ready schizophrenia drug

Boehringer's decision to turn down its chance to license the phase 2-ready schizophrenia candidate deprived Nxera of a 60 million euro option payment.
Nick Paul Taylor Dec 19, 2025 6:35am
Brain wrapped in cash money

Schizophrenia-minded Syremis takes off with $165M series A

Dec 18, 2025 12:59pm
IPO initial public offering

MapLight goes public via $250M IPO to fund Cobenfy competitor

Oct 27, 2025 6:45am
schizophrenia mental health brain neurodegenerative

Boehringer, Click DTx hits phase 3 goal in schizophrenia

Oct 14, 2025 12:08pm
3D Rendering futuristic robot technology development artificial intelligence

MapLight illuminates $262M IPO plans to fund Cobenfy competitor

Oct 7, 2025 6:30am
IPO initial public offering Wall Street

Big Pharma-backed MapLight plots IPO

Sep 22, 2025 1:57pm